Back to Journals » OncoTargets and Therapy » Volume 9

Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis

Authors Liang J, Liang Y, Gao W

Received 12 December 2015

Accepted for publication 18 March 2016

Published 24 May 2016 Volume 2016:9 Pages 3113—3125

DOI https://doi.org/10.2147/OTT.S102389

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Triparna Sen

Peer reviewer comments 2

Editor who approved publication: Professor Min Li


Jin-xiao Liang,1 Yong Liang,2 Wei Gao3

1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China; 2Department of Clinical Medicine, Taizhou University Medical School, Taizhou, People’s Republic of China; 3School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, People’s Republic of China

Abstract: Many studies have shown that sialyl Lewis X (sLeX) is related to cancer prognosis and clinicopathology, but failed to provide conclusive results. We conducted the present meta-analysis to identify the association between sLeX overexpression and cancer prognosis. We searched studies in PubMed and Embase databases. Relative risk or hazard ratio with 95% confidence intervals were estimated with the Mantel–Haenszel random-effect method and 29 studies were included. Our meta-analysis showed that sLeX overexpression is significantly related to lymphatic invasion, venous invasion, T stage, N stage, M stage, tumor stage, recurrence, and overall survival. In subgroup analysis, we found that cancer type and ethnicity might be two major contributing factors to the possible presence of heterogeneity among the studies. In conclusion, sLeX overexpression is associated with tumor metastasis, recurrence, and overall survival in cancer patients, it plays an important role in cancer prognosis.

Keywords: sialyl Lewis X, cancer, prognosis, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]